

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 January 2024 (11.01.2024)



(10) International Publication Number
WO 2024/008929 A1

(51) International Patent Classification:

A61K 31/506 (2006.01) A61K 31/53 (2006.01)
A61K 31/4985 (2006.01) A61K 31/5377 (2006.01)
A61K 31/517 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2023/068862

(22) International Filing Date:

07 July 2023 (07.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/367,949 08 July 2022 (08.07.2022) US
63/370,501 05 August 2022 (05.08.2022) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; 151 85
Södertälje (SE).

(72) Inventors: **HARTMAIER, Ryan**; AstraZeneca Pharma-
ceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilming-
ton, Delaware 19850-5437 (US). **DANGELO, Gina**; As-
traZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O.
Box 15437, Wilmington, Delaware 19850-5437 (US).


(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-
TY**; Eastbrook House Shaftesbury Road, Cambridge Cam-
bridgeshire CB2 8BF (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN COMBINATION WITH HGF-
RECEPTOR INHIBITORS FOR THE TREATMENT OF CANCER

Figure 1



(57) Abstract: The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of cancer, wherein the EGFR TKI is administered in combination with an inhibitor of c-MET.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*